Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4+ T cell response in all vaccinees

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F25%3A10496696" target="_blank" >RIV/00216208:11110/25:10496696 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/25:10496696 RIV/00064203:_____/25:10496696 RIV/00064165:_____/25:10496696

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=urLR3hnq8h" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=urLR3hnq8h</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ajt.2025.03.025" target="_blank" >10.1016/j.ajt.2025.03.025</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4+ T cell response in all vaccinees

Popis výsledku v původním jazyce

Respiratory syncytial virus (RSV) causes seasonal acute respiratory illness significantly impacting vulnerable groups, including lung transplant recipients (LTRs), who are at increased risk of hospitalization, acute rejection, and allograft dysfunction. The immunogenicity of the novel RSV Prefusion F3 (RSVPreF3-AS01, Arexvy, GlaxoSmithKline) vaccine in immunocompromised patients remains largely unknown. In this study, we assessed both antibody using and cellular immune responses two months after a single dose of the RSVPreF3-AS01 vaccine in 30 LTRs aged 60 years or older, who were at least six months post-transplant. The antibody response was assessed using enzyme-linked immuno sorbent assay for detection of serum anti RSV-F IgG specific antibodies, and the CD4+ T-cell response was measured by flow cytometry intracellular cytokine secretion assay. Our findings show that all vaccinees exhibited a CD4+ T-cell response two months post-vaccination, while only 40% demonstrated an antibody response. These results suggest that some patients may derive clinical benefit from the vaccine through cellular immunity, even without an antibody response. Furthermore, the vaccine was well tolerated in this vulnerable population, with no major safety concerns observed.

Název v anglickém jazyce

Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4+ T cell response in all vaccinees

Popis výsledku anglicky

Respiratory syncytial virus (RSV) causes seasonal acute respiratory illness significantly impacting vulnerable groups, including lung transplant recipients (LTRs), who are at increased risk of hospitalization, acute rejection, and allograft dysfunction. The immunogenicity of the novel RSV Prefusion F3 (RSVPreF3-AS01, Arexvy, GlaxoSmithKline) vaccine in immunocompromised patients remains largely unknown. In this study, we assessed both antibody using and cellular immune responses two months after a single dose of the RSVPreF3-AS01 vaccine in 30 LTRs aged 60 years or older, who were at least six months post-transplant. The antibody response was assessed using enzyme-linked immuno sorbent assay for detection of serum anti RSV-F IgG specific antibodies, and the CD4+ T-cell response was measured by flow cytometry intracellular cytokine secretion assay. Our findings show that all vaccinees exhibited a CD4+ T-cell response two months post-vaccination, while only 40% demonstrated an antibody response. These results suggest that some patients may derive clinical benefit from the vaccine through cellular immunity, even without an antibody response. Furthermore, the vaccine was well tolerated in this vulnerable population, with no major safety concerns observed.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30212 - Surgery

Projekt

<a href="/cs/project/NU22-05-00402" target="_blank" >NU22-05-00402: Specifická imunitní odpověď po očkování proti virovým patogenům u imunokompromitovaných pacientů</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American Journal of Transplantation

ISSN

1600-6135

e-ISSN

1600-6143

Svazek periodika

25

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

1452-1460

Kód UT WoS článku

001532622900001

EID výsledku v databázi Scopus

2-s2.0-105003209371